Listen on Apple Podcasts

Listen on Spotify

After contracting COVID-19 despite being vaccinated and boosted, Grammy-nominated artist Aloe Blacc attempted to fund research for improved treatments. He soon discovered that simply writing a check isn't feasible in biotechnology. Regulatory bodies demand a detailed commercialization strategy, and philanthropic donations alone cannot advance scientific research through clinical trials or secure licensing for university intellectual property. Currently, he is self-funding a cancer drug platform focused on pancreatic cancer, which has a staggering 90% mortality rate. He is deliberately postponing fundraising from his connections until peer-reviewed publications can substantiate his approach.

Tune into the complete episode to learn:

How he is establishing credibility in a field where data, not celebrity status, is paramount

How a molecular discovery platform at the University of Houston has the potential to significantly shorten drug development timelines

His perspective that record labels, rather than artists or AI firms, will ultimately govern the financial dynamics of AI-generated music

What his experience with Suno revealed about prototyping, and why his upcoming album will continue to feature live musicians

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify, and other podcast platforms. You can also follow Equity on X and Threads at @EquityPod.